ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2430

Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus

Steven Beiser1, Asma Qureshi1, Komel Safdar2, Zachary Orban1, Mary Carns2, Vanessa Manada De Lobos1, Cecilia Stumpf3, Mohammad Daud Khan1, Tyler Therron4, Anh Chung1, Katherine Puev1, Neil Pillai1, Kathleen Aren5, John F Seagrist2, Jing Song6, Jason Ross1, Harris R Perlman2, Yvonne Lee2, Deborah Rachelle Winter7, Borna Bonakdarpour1, Mariam Siddiqui8, Laura Arneson2, Rosalind Ramsey-Goldman9, Lutfiyya muhammad9, Mary Mahieu9, Irene Blanco10, Eric Larson1, Elena Grebenciucova1 and Carla Marie Cuda2, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL, 3Northwestern University, Elmhurst, IL, 4Northwestern Feinberg School of Medicine, Chicago, IL, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Northwestern University Feinberg School of Medicine, Worthington, MN, 7Northwestern University, Skokie, IL, 8Northwestern, Chicago, IL, 9Northwestern University Feinberg School of Medicine, Chicago, IL, 10Northwestern University, Oak Park, IL

Meeting: ACR Convergence 2025

Keywords: Cognitive dysfunction, complement, Disease Activity, Neuropsychological Assessment, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity. NIH Toolbox for Assessment of Neurological and Behavioral Function (NIHT) is widely utilized to monitor CI in conditions like Alzheimer’s disease and long COVID, yet few reports address its value in measuring CI in SLE. Further, the relationship between NIHT’s subdomains and SLE disease activity has yet to be explored. We hypothesize that NIHT can effectively characterize CI in persons with and without active SLE and help clarify if disease activity contributes to poor cognitive performance. A secondary aim is to identify serum and cerebrospinal fluid (CSF) biomarkers mediating immune-related neuropathology.

Methods: Cross-sectional data were analyzed from adult patients enrolled in our ongoing study of immune-mediated mechanisms of neuropsychiatric SLE. Eligible participants met 4 of 11 ACR 1997 or 3 of 11 ACR 1997 with SLICC 2012 criteria for SLE and did not have concurrent autoimmune or neurologic diseases, active or chronic infections, GFR< 60, liver enzymes >3× ULN, or sodium imbalance. Cognitive performance was assessed by the clinically validated Montreal Cognitive Assessment (MoCA), reported as total score, and a targeted NIHT battery, reported as age-adjusted standard scores. SLEDAI-2K≥6 defined moderate-high disease activity; SLEDAI-2K< 6 indicated low-moderately active or inactive disease. Note, only one participant scored for a neurological SLEDAI-2K descriptor. Descriptive statistics summarized demographic and clinical characteristics. Spearman correlations assessed relationships between continuous variables. Associations between continuous and categorical variables were assessed via Wilcoxon rank sum tests.

Results: Our sample included 22 female patients with SLE free of concurrent autoimmune or neurologic disease with mean (SD) age of 33.8 (11.8) years and disease duration of 8.9 (6.0) years (Table 1). Patients with moderate-high disease activity scored lower on the Dimensional Change Card Sort and Rey Auditory Verbal Learning Tests for executive function and delayed auditory-verbal memory, respectively, compared to those with inactive or low-moderate disease activity (Table 2,4). SLEDAI subcomponent scores did not associate with altered CI subdomains (Table 3). Yet, low circulating complement C4 correlated with worse delayed auditory-verbal memory. Findings were independent of demographic, patient-reported, clinical, and other lab characteristics (Table 2,4). MoCA did not differentiate groups, highlighting NIHT’s superior sensitivity.

Conclusion: The NIHT is a domain-specific, sensitive tool for detecting CI in SLE, outperforming the MoCA. Higher SLEDAI, but not subcomponent, scores correlate with executive function and memory impairments, supporting a role for generalized inflammation, and potentially C4, in SLE-related CI. Here, we advance the field by exploring the link between SLE disease activity and CI of domains essential for daily functioning and expanding immune profiling of serum and CSF to clarify the neuroimmune basis of these deficits.

Supporting image 1Tables 1

Supporting image 2Table 2-4


Disclosures: S. Beiser: None; A. Qureshi: None; K. Safdar: None; Z. Orban: None; M. Carns: None; V. Manada De Lobos: None; C. Stumpf: None; M. Khan: None; T. Therron: None; A. Chung: None; K. Puev: None; N. Pillai: None; K. Aren: None; J. Seagrist: None; J. Song: None; J. Ross: None; H. Perlman: AbbVie/Abbott, 2; Y. Lee: CVS Health, 12,, GE Healthcare, 12,, Tonix, 1; D. Winter: None; B. Bonakdarpour: None; M. Siddiqui: None; L. Arneson: Novartis, 12,; R. Ramsey-Goldman: Ampel Solutions, 2, AstraZeneca, 6, Biogen, 2, Cabaletta, 2, Duke, 2, Exagen Diagnostics, 2, Merck, 2, SUNY Syracuse, 2; L. muhammad: None; M. Mahieu: None; I. Blanco: Cabaletta Bio, 5, Fate Therapeutics, 2, Novartis, 5, Zenas BioPharma, 2; E. Larson: None; E. Grebenciucova: Amgen, 6, AstraZeneca, 6, Genentech, 6, Tg therapeutics, 6; C. Cuda: None.

To cite this abstract in AMA style:

Beiser S, Qureshi A, Safdar K, Orban Z, Carns M, Manada De Lobos V, Stumpf C, Khan M, Therron T, Chung A, Puev K, Pillai N, Aren K, Seagrist J, Song J, Ross J, Perlman H, Lee Y, Winter D, Bonakdarpour B, Siddiqui M, Arneson L, Ramsey-Goldman R, muhammad L, Mahieu M, Blanco I, Larson E, Grebenciucova E, Cuda C. Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/disease-activity-independently-correlates-with-cognitive-impairment-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-independently-correlates-with-cognitive-impairment-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology